Our company is committed to the in-house development of all elemental technologies, including our proprietary non-contact and non-invasive biomarker measurement technology.
We are pleased to inform you that we have strengthened our collaboration with the international medical institutions with which we are conducting joint clinical research, and have decided to provide measurement and analysis data concerning LDL cholesterol as a new indicator category to the university.
The item we intend to provide this time is “LDL cholesterol,” which serves as an essential indicator for assessing the risk of arteriosclerosis.
Our company will continue to strive to maintain our technological and temporal advantages, enhance accuracy and precision, and advance our technology further.
For more details, information will be disseminated within the scope of approval from all relevant parties.